Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2

[en] Sodium-glucose cotransporter type 2 (SGLT2) inhibitors (SGLT2i; gliflozins) exert their glucose-lowering effect by enhancing glucosuria. Beyond improving glucose control, they are associated with other metabolic and haemodynamic effects that are potentially beneficial. Empagliflozin (EMPA-REG OUTCOME) and canagliflozin (CANVAS) have shown significant reductions in major cardiovascular events, hospitalisation for heart failure and renal outcomes in patients with type 2 diabetes and high cardiovascular risk. Dapagliflozin (preliminary positive effects reported in the observational CVD-REAL registry) is currently evaluated in the DECLARE-TIMI 58 cardiovascular outcome trial. Gliflozins may be used in combination with metformin or a sulphonylurea, in triple oral therapy or in combination with basal insulin according to recent international guidelines. They should most probably be preferred in patients with established cardiovascular disease, at high risk of heart failure and/or with mild renal impairment. Their use is contra-indicated in case of more severe renal insufficiency and in patients with recurrent urinary or genital infections. As they as not commercialized in France yet, SGLT2i were not included in the position statement published by the French-speaking diabetes society (SFD) late 2017. This article analyses the different potential and preferential uses of SGLT2i according to recent data of evidence-based medicine and the clinical experience in French-speaking countries where they are already available. © 2018 Elsevier Masson SAS

Disciplines :

Cardiovascular & respiratory systems
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2

Alternative titles :

[en] Positioning SGLT2 inhibitors in the management of type 2 diabetes

Publication date :

2018

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson SAS

Volume :

Issue :

Pages :

22-30

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 03 December 2018

Statistics

Number of views

88 (3 by ULiège)

Number of downloads

2235 (14 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Scheen, A.J., Antidiabétiques oraux dans le traitement du diabète de type 2: perspectives historique et médico-économique. Médecine des maladies Métaboliques 9 (2015), 186–197.
Scheen, A.J., Pharmacological management of type 2 diabetes: what's new in 2017?. Expert Rev Clin Pharmacol 10 (2017), 1383–1394.
Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
Garber, A.J., Abrahamson, M.J., Barzilay, J.I., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 Executive Summary. Endocr Pract 23 (2017), 207–238.
Qaseem, A., Barry, M.J., Humphrey, L.L., et al. Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166 (2017), 279–290.
Darmon, P., Bauduceau, B., Bordier, L., et al. Société Francophone du Diabète (SFD). Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. Médecine des maladies Métaboliques 11 (2017), 577–593.
Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A., Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32 (2011), 515–531.
Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
Heerspink, H.J., Perkins, B.A., Fitchett, D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects. Potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
Scheen, A.J., Historique des études cardiovasculaires: de l'UGDP … aux dernières études. Médecine des maladies Métaboliques, 11(Suppl.1), 2017 2S15-2S26.
Zinman, B., Wanner, C., Lachin, J.M., et al. EMPA-REG. OUTCOME. Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
Neal, B., Perkovic, V., Mahaffey, K.W., et al. CANVAS Program Collaborativeg Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
Kosiborod, M., Cavender, M.A., Fu, A.Z., et al. CVD-REAL Investigators and Studyg Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
Birkeland, K.I., Jørgensen, M.E., Carstensen, B., et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
Persson, F., Nyström, T., Jørgensen, M.E., et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes patients (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab, 2017 Aug 3 [Epub ahead of print].
Palmer, S.C., Mavridis, D., Nicolucci, A., et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
Scheen, A.J., SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol 1 (2013), 168–170.
Paquot, N., Scheen, A.J., Inhibiteur de la DPP-4 ou des SGLT2 après échec de la metformine seule dans le diabète de type 2. Rev Med Suisse 13 (2017), 1410–1415.
American Diabetes, Association, Standards of medical care in diabetes-2017. Diabetes Care 40:Suppl.1 (2017), S1–S135.
Scheen, A.J., Paquot, N., Le choix entre un inhibiteur de la DPP-4 et un inhibiteur des SGLT2 pour traiter le diabète de type 2. Rev Med Liege 71 (2016), 579–585.
Scheen, A.J., Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opin Pharmacother 18 (2017), 503–515.
Scheen, A.J., ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?. Diabetes Metab 43 (2017), 295–297.
Scheen, A.J., DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol 12 (2016), 1407–1417.
Scheen, A.J., Paquot, N., Combinaison gliptine-gliflozine dans le traitement du diabète de type 2. Rev Med Suisse 12 (2016), 1384–1388.
Tang, H., Cui, W., Li, D., et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 19 (2017), 142–147.
Scheen, A.J., Paquot, N., Options thérapeutiques chez un patient diabétique de type 2 mal contrôlé par une insuline basale. Rev Med Suisse 13 (2017), 1416–1420.
Min, S.H., Yoon, J.H., Hahn, S., Cho, Y.M., Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev, 33, 2017, e2818.
Gurgle, H.E., White, K., McAdam-Marx, C., SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag 12 (2016), 239–249.
Tan, X., Hu, J., Empagliflozin/linagliptin: Combination therapy in patients with type 2 diabetes. Ann Endocrinol (Paris) 77 (2016), 557–562.
Scheen, A.J., Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Rev Clin Pharmacol 10 (2017), 1303–1316.
Scheen, A.J., Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 13 (2017), 583–592.
DeFronzo, R.A., Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 19 (2017), 1353–1362.
Frías, J.P., Guja, C., Hardy, E., et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4 (2016), 1004–1016 [Erratum in: Lancet Diabetes Endocrinol 2017;5:e8].
Yang, Y., Chen, S., Pan, H., et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore), 96, 2017, e6944.
Dandona, P., Mathieu, C., Phillip, M., et al. DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 5 (2017), 864–876 [Erratum in: Lancet Diabetes Endocrinol 2017;5:e8].
Garg, S.K., Henry, R.R., Banks, P., et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377 (2017), 2337–2348.
Wu, J.H., Foote, C., Blomster, J., et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 4 (2016), 411–419.
Scheen, A.J., Ernest, P., Jandrain, B., Protection cardio-rénale par les inhibiteurs des SGLT2 (gliflozines): d'EMPA-REG OUTCOME à CANVAS. Rev Med Suisse 13 (2017), 1421–1426.
Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab 42 (2016), 71–76.
Scheen, A.J., Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME: Comparison with classic diuretics. Diabetes Metab 42 (2016), 224–233.
Scheen, A.J., Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 121 (2016), 204–214.
Fitchett, D., Zinman, B., Wanner, C., et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37 (2016), 1526–1534.
Scheen, A.J., GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab, 43(Suppl.1), 2017 2S13-2S19.
Ponikowski, P., Voors, A.A., Anker, S.D., et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200 [Erratum in: Eur Heart J 2016: ehx158].
Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
Scheen, A.J., Delanaye, P., Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab 43 (2017), 99–109.
Scheen, A.J., SGLT2 inhibitors: benefit/risk balance. Curr Diabetes Rep, 16, 2016, 92.
Filippas-Ntekouan, S., Filippatos, T.D., Elisaf, M.S., SGLT2 inhibitors: are they safe?. Postgrad Med 130 (2018), 72–82.
Li, D., Wang, T., Shen, S., et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 19 (2017), 348–355.
Fadini, G.P., Bonora, B.M., Mayur, S., et al. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab, 2017 Oct 20 [Epub ahead of print].
Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38 (2015), 1638–1642.
Qiu, H., Novikov, A., Vallon, V., Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev, 33, 2017, e2886.
Fadini, G.P., Bonora, B.M., Avogaro, A., SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 60 (2017), 1385–1389.
Jabbour, S., Seufert, J., Scheen, A., et al. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab, 2017 Sep 26 [Epub ahead of print].
Deeks, E.D., Scheen, A.J., Canagliflozin: a review in type 2 diabetes. Drugs 77 (2017), 1577–1592.
Yuan, Z., DeFalco, F.J., Ryan, P.B., et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab, 2017 Sep 12 [Epub ahead of print].